GeoVax Labs reports third quarter net loss and lower revenue

Reuters

11/14

GeoVax Labs reports third quarter net loss and lower revenue

GeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583510798"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583510798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583510798?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583510798","market":"us","top_or_hot":-1,"title":"GeoVax Labs reports third quarter net loss and lower revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeoVax Labs reports third quarter net loss and lower revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GOVX\">GeoVax Labs Inc</a>. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOVXW\">GeoVax Labs Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeoVax Labs reports third quarter net loss and lower revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeoVax Labs reports third quarter net loss and lower revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 06:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeoVax Labs reports third quarter net loss and lower revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GOVX\">GeoVax Labs Inc</a>. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOVXW\">GeoVax Labs Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3mxvYY:1","article_id":"2583510798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583510798","pubTimestamp":1763072494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4139":"生物科技","GOVX":"GeoVax Labs Inc"},"translate_title":"GeoVax Labs报告第三季度净亏损和收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOVX":0.9},"content_text":"GeoVax Labs reports third quarter net loss and lower revenue\n    \n\nGeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}